Objectives: Early discharge of patients with presentations triggering assessment for possible acute coronary syndrome (ACS) is safe when clinical assessment indicates low risk, biomarkers are negative, and electrocardiograms (ECGs) are nonischemic. We hypothesized that the Emergency Department Assessment of Chest Pain Score (EDACS) combined with a single measurement of high-sensitivity cardiac troponin (hs-cTn) could allow early discharge of a clinically meaningful proportion of patients.
D iagnostic pathways to rapidly assess patients presenting with symptoms suggestive of acute coronary syndrome (ACS) are transforming practice. Pathways, often referred to as accelerated diagnostic protocols (ADPs), have been developed that facilitate early decision making for chest pain patients. ADPs incorporate formal risk assessment scores along with the electrocardiogram (ECG) and serial cardiac troponins, usually 2 or more hours apart, where both troponin concentrations are less than the upper reference limit. [1] [2] [3] Australasian and European guidelines have recommended strategies based on serial measurements of hs-cTn with "rule-out" based on very low values with little or no change over 1 to 4 hours. 4, 5 These strategies recommend taking into account clinical characteristics (although these are not specifically defined). Most recently, U.K.'s National Institute for Health and Care Excellence (NICE) recommended the use of a single high-sensitivity troponin below the limit of detection LoD in combination with a validated risk assessment tool could be used to discharge patients even earlier than current serial troponin strategies. 6 This acknowledges the importance of incorporating evidence-based, structured clinical assessments to assist rule-out of acute myocardial infarction (AMI). 7 There are many studies that rule out acute MI using a single troponin below a specified threshold at far below the 99th percentile upper reference limit, [8] [9] [10] [11] [12] [13] [14] [15] [16] but none that combine a single measurement with a clinical risk score to 1) allow that very low threshold to be raised above the LoD and 2) not only rule out MI, but also identify patients with a very low risk of 30-day adverse events.
The Emergency Department Assessment of Chest Pain Score (EDACS) was developed for the express purpose of facilitating the early discharge of patients at low risk of AMI and/or major adverse cardiac events (MACE) within 30 days. 17 It has been shown to be at least as efficacious as the Thrombolysis In Myocardial Infarction (TIMI) score in a randomized controlled trial 3 and has been validated in several international studies. [18] [19] [20] [21] Serial troponin pathways using the EDACS are in use in most emergency departments (EDs) in New Zealand 22 and three hospitals in Iran and are under assessment in Italy and Australia.
For each of the two currently commercially available high-sensitivity troponin assays, we aimed to identify the optimal combination of EDACS with a single initial troponin concentration, which may be above the LoD, and ECG to classify patients at low risk of myocardial infarction on presentation to the ED.
METHODS

Study Design
This study is a post hoc analysis of prospectively collected data from a two-center two-country observational study (ADAPT 2 ) and from two single-center randomized controlled trials (ADAPT-ADP 23 and EDACS-ADP 3 ) of patients with symptoms of possible ACS who attended an ED.
Study Aim
To find the combination of hs-cTn and EDACS thresholds (considering high-sensitivity cardiac troponin I [hs-cTnI] and high-sensitivity cardiac troponin T [hs-cTnT] separately) which, with a minimum prespecified sensitivity, maximized the percentage of patients who could be classified as low risk for a MACE within 30 days of presentation.
Study Setting and Population
The inclusion and exclusion criteria were almost identical for each study; briefly, eligible patients were ≥18 years old (without ST-elevation AMI or likely noncoronary pathology), who presented acutely from the community to the ED with symptoms suggestive of ACS and whom the attending physician(s) planned to investigate with serial cardiac troponin tests. Participants were followed up by telephone and through hospital readmissions records for 30 days. For this analysis, to allow more direct comparison between troponin assays, we limited the cohort to patients in whom both an hs-cTnI and hs-cTnT concentration on presentation was available. We included only patients with no new ischemic ECG changes (we considered patients with ischemic changes as not low risk).
Study Protocol
On presentation, blood was collected in lithiumheparin tubes, immediately centrifuged, and stored at -80°C. Troponin I concentrations were measured by the Abbott ARCHITECT high-sensitivity troponin I (Abbott Diagnostics) assay (hs-cTnI). Troponin T concentrations by the Roche fifth-generation troponin T (Roche Diagnostics) assay (hs-cTnT) on the Roche Elecsys system. These assays are often referred to as "high sensitivity" and measure low concentrations with higher accuracy than previous generations of assay. 24 Note, this analytic use of "high-sensitivity" should not be confused with the performance sensitivity, meaning the percentage of patients with the event of interest who are correctly diagnosed (true positives) at a particular troponin concentration threshold. The manufacturer reported LoD and 99th percentile URL of the hs-cTnT assay are 5 and 14 ng/L, respectively. 25 The hs-cTnI assay has a LoD of 1.9 ng/L and sex-specific URL of 16 ng/L for women and 34 ng/L for males and an overall URL of 26 ng/L. 26, 27 Key Outcome Measures The primary composite outcome was a MACE within 30 days defined as AMI, cardiac arrest, cardiogenic shock, emergency revascularization, ventricular arrhythmia requiring intervention, high-degree atrioventricular block needing intervention, or death (unless clearly noncardiac). 3, 17 Classification of AMI was based on the global task force universal definition for AMI, requiring evidence of a rise and/or fall in troponin concentration with at least one concentration above the 99th percentile together with evidence of myocardial ischemia (ischemic symptoms, ECG changes, or imaging evidence). 28 The reference troponin assay used for the clinical adjudication of an AMI diagnosis for the ADAPT study and ADAPT-ADP RCT was the fourth generation (not "high sensitivity") ARCHITECT troponin I (Abbott Diagnostics) and for the EDACS-ADP RCT the ARCHITECT high-sensitivity troponin I (Abbott Diagnostics). Two senior clinicians independently adjudicated the index event and all follow-up admissions for the presence of MACE. A third adjudicator was used to resolve differences. The same standardized definitions were used for all variables and procedures. 29 
Risk Assessment
On presentation to the ED, patients underwent ECG, blood was drawn for later analysis, and both demographics and clinical risk factors were recorded by research nurses. ECG results were defined as negative or positive according to the presence of new ischemic ECG changes. New ECG changes were defined as STsegment depression of at least 0.05 mV in two or more contiguous leads (including reciprocal changes), T-wave inversion of at least 0.1 mV, or Q-waves greater than 30 milliseconds in width and 0.1 mV or greater in depth in at least two contiguous leads. Abnormalities that were present on available preexisting ECGs were not defined as new ischemia. The EDACS was calculated for each patient based on clinical variables collected at the time of presentation (Table 1) .
Data Analysis
The index test comprising hs-cTn and EDACS was considered positive if either the hs-cTn concentration was greater than or equal to an hs-cTn threshold or an EDACS was greater than or equal to an EDACS threshold. These patients were categorized as "not low risk." Therefore, low-risk patients (negative index test) were those with hs-cTn below the hs-cTn threshold and EDACS less than the EDACS threshold.
We determined a priori that at we would exclude patients with an ischemic event on the ECG and use a sensitivity of 98.5% to determine the combination of hs-cTn and EDACS thresholds maximizing the percentage low risk, called the "optimal combination." This was for pragmatic reasons as patients with positive ECGs are not considered low risk and the methodology chosen means that it was not possible to include ischemic ECG (a binary outcome) as an additional dimension (along with EDACS and hs-cTn). Some research has suggested a sensitivity of 99.0% (i.e., a 1% miss rate of events) as a de facto minimum standard for algorithms to classify patients as low risk for AMI. 30 However, in that study, opinions of acceptable miss rates ranged up to 2%. 31 Because approximately one-third of those with a myocardial infarction had a positive ECG, the removal of these results in a 99.0% sensitivity decreasing to 98.5%.
We varied the hs-cTn threshold across its range from the LoD to its maximum value in ng/L, and we varied the EDACS from its minimum possible value (-8) to its maximum possible value (34) . At each combination of hs-cTn threshold and EDACS threshold we calculated the sensitivity and specificity for 30-day MACE.
All studies establishing diagnostic thresholds for a very high sensitivity (i.e., low number of false negatives) are sensitive to small variations in either the hscTn or EDACS and also to any variation in the reference standard for AMI. 32 Therefore, we determined a priori to create 500 bootstraps of the data and to average the results. Bootstrapping involves creating multiple data sets by repeatedly randomly selecting patients from the original data set with replacement. 32 Each bootstrapped data set has the same number of patients as the original data set, although some patients are repeated more than once and some do not appear at all. With each bootstrapped sample, we used twodimensional Gaussian kernel density estimation 33, 34 (the hs-cTn threshold and EDACS threshold dimensions) for those incurring a MACE and for those spared a MACE to obtain smoothed estimates of the numbers of patients at each threshold combination with and without a MACE. We used the log (base 10) value of the hs-cTn threshold to aid fitting. From this we determined the sensitivities for 30-day MACE and percentages of low risk at each combination of thresholds and for each bootstrapped data set. We averaged these sensitivities and then fitted the 98.5% sensitivity contour (the line on the hs-cTn threshold-EDACS threshold grid of sensitivity equaling 98.5%) and contours for percentage low risk. Statistical calculations were made in R version 3.2.4 (with package "MASS," function kde2d with the bandwidths for each dimension determined by the normal reference distribution 35 ). We compared the performance of the combined strategy with the LoD strategy, where low risk is defined hs-cTn < the LoD of the assay (i.e., not considering a higher threshold or EDACS at all).
Several possible combinations of hs-cTn and EDACS were expected to also have a 98.5% sensitivity for MACE, although only one combination would optimally maximize the proportion of patients classified as low risk. We evaluated if more patients could be classified low risk if results met the low-risk criteria for any of the threshold combinations that gave 98.5% sensitivity for MACE, and if so, whether the overall sensitivity would be maintained. We further evaluated if better sensitivity could be obtained by requiring that low-risk classification only be met if the low-risk criteria for all of the threshold combinations have 98.5% sensitivity for MACE.
RESULTS
Study Patients
Of 2,536 patients with both hs-cTnI and hs-cTnT measured on presentation to the ED, 433 (17.1%) incurred a MACE within 30 days of presentation. The patients were typically male with a history of dyslipidemia, family history of coronary artery disease, and hypertension ( Table 2 ). The first blood draw was 3 hours beyond symptom onset in 82.1% of patients. There were 278 (11.0%) patients with a positive ECG (including 161 with 30-day MACE), leaving 2258 patients (272 [12. 1%] with 30-day MACE) in which optimal combinations of hs-cTn and EDACS thresholds were determined. Figure 1 illustrates that even in these large data, estimation techniques are needed to determine optimal thresholds. Kernal density estimates combined with bootstrapping produces smooth contour lines of sensitivity on the hs-cTn threshold versus EDACS threshold plots (Figure 2A and 2C) . Figures 2B and 2D plot the percentage low risk along the 98.5% sensitivity curve as a function of the hs-cTn and EDACS.
ACADEMIC EMERGENCY MEDICINE
For hs-cTnI, the percentage low risk at 98.5% sensitivity is maximal (36.8%) for a combination of a threshold of 7.0 ng/L with an EDACS threshold of 16 (peak of the curves in Figure 2B ). For hscTnT, the percentage low risk at 98.5% sensitivity is maximal (30.3%) for a combination of a threshold of 8.3 ng/L with an EDACS threshold of 15 (peak of the curve in Figure 2D ). Because high-sensitivity troponin concentrations are normally reported as whole numbers, a threshold of 8 ng/L would be more appropriate.
Internal Validation
The hs-cTnI combination of <7.0 ng/L and EDACS < 16 in the 500 bootstrapped samples classified 35.2% (33.4%-37.0%) low risk consistent with the percentage obtained above, with a sensitivity of 98.7% (97.7%-99.4%). Similarly, the hs-cTnT combination of < 8.3 ng/L and EDACS < 15 in the 500 bootstrapped samples classified 29.2% (27.5%-30.9%) low risk with a sensitivity of 98.5% (97.5%-99.4%).
hs-cTn Alone at the LoD
In the bootstrapped samples hs-cTnI < LoD classified 14.1% (13.7%-14.7%) as low risk with a sensitivity of 100% (98.6%-100%) with. Similarly, hs-cTnT < LoD classified 33.7% (33.0%-34.4%) as low risk with a sensitivity of 98.6% (98.1%-99.0%).
Multiple Threshold Combinations
For each of hs-cTnI and hs-cTnT several other combinations with EDACS also classified many patients as low risk with a sensitivity of 98.5% (Figures 2B and  2D ; Table 3 ). We limited these combinations to those with an EDACS threshold within two of the optimal EDACS threshold.
If patients met any of the five threshold combinations with hs-cTnI and EDACS then 46.6% were classified as low risk but at the cost of a lower sensitivity, 96.4% (93.4%-98.3%) (i.e., this means missing 3.6% of true MACE events; Table 3 ). Similarly, for five combinations of hs-cTnT and EDACS 40.4% were classified as low risk with a sensitivity of 96.7% (93.8%-98.5%). Sensitivity was increased if patients had to meet all the hs-cTnI and EDACS threshold combinations, 99.6% (97.9%-100%) with reduced percentage low risk at only 24.9%. Similarly, for hscTnT and EDACS threshold combinations where Data are reported as mean AE SD or number (%). CAD = coronary artery disease; MI = myocardial infarction. patients met all combinations the sensitivity was 99.6% (97.9%-100%) and percentage low risk 20.7%.
DISCUSSION
These data suggest that the combination of a low EDACS and a single hs-cTn concentration measured on presentation to the ED can safely and effectively classify more than 30% of patients being assessed for possible ACS as at low risk of 30-day MACE. This has the potential to accelerate decision making, reduce overcrowding in EDs, and rapidly reassure a large portion of patients that they are not suffering a myocardial infarction. EDACS combined with hs-cTnI classified more patients as low risk (36.8%) than EDACS combined with hs-cTnT (30.3%).
Rather than relying on the analytical LoD of the assay or the URL of the assay to guide decision making, as with most other single-troponin strategies, we have derived an optimal threshold in combination with EDACS. The importance of the methodology used to find these thresholds, bootstrapping and using a smoothing function, is highlighted by Figure 1 , where the vertical lines for the sensitivity contours show that a small change in EDACS threshold would result in a large change of hs-cTn threshold for the same sensitivity. Without the statistical procedure used there is great potential for choosing hs-cTn and EDACS thresholds that are not reproducible in future studies.
The European Society of Cardiology (ESC) and the NICE have produced guidelines which include an algorithm that allows immediate "rule-out" of incident MI for hs-cTnI < 2 ng/L or hs-cTnT < 5 ng/L (i.e., at the LoD of each assay). 4, 5 In our current study the sensitivity for both hs-TnI and hs-TnT using the LoD strategy was comparable with the strategy of an hs-cTn combined with EDACS. However, the proportion Figure 2 . Fitted 98.5% sensitivity (blue) and specificity (red) contour lines on the grid of (A) hs-cTnI or (C) hs-cTnT and EDACS thresholds. Graphs (B) and (D) plot the percentage low risk along the 98.5% contour line from graphs (A) and (C), respectively, as a function of the hs-cTn threshold (brown) and EDACS (green). Three combinations of hs-cTn and EDACS are illustrated by the arrows. For example, for hs-cTnI at 4.5 ng/L the corresponding EDACS threshold is (just over) 17. The optimal combination of hs-cTnI with EDACS is 7.0 ng/L and 16. For example, the percentage of patients with hs-cTnI < 7 and EDACS < 16 is the maximum for any combination of hs-cTnI and EDACS. Similarly the optimal combination of hs-cTnT and EDACS is 8.4 ng/L and 15. EDACS = Emergency Department Assessment of Chest Pain Score; hs-cTnI = highsensitivity cardiac troponin I; hs-cTnT = high-sensitivity cardiac troponin T. [Color figure can be viewed at wileyonlinelibrary.com]
classified as low risk was lower for hs-cTnI, yet comparable for hs-cTnT. We have shown that the LoD component of the guidelines performed safely, 36, 37 and various studies investigating only the LoD threshold have high sensitivity and NPV (e.g., Body et al., 8 Rubini Gimenez et al., 10 Sandoval et al.
12
), but this is not always the case. 38 The 5 ng/L hs-cTnI threshold has been shown to have a large NPV in a large European study.
14 However, in a multinational study, the sensitivity for this strategy was only 95% (92%-97%). 39 This highlights the importance of the ESC recommendation that algorithms be used "in conjunction with all available clinical information, including detailed assessment of chest pain characteristics and ECG." 5 This recommendation is nonspecific and reintroduces substantial subjectivity; moreover, the NICE has recently specified the use of a validated risk assessment tool. 6 While a single biomarker does not substitute for clinical judgment, 40 and is in any case unlikely to be a widely accepted strategy, clinical gestalt alone is also inadequate. 7 For these reasons we investigated the combination of a single hs-cTn with a validated risk score.
Recently, in one study, a TIMI score of 0 combined with the LoD of the assay used as a threshold resulted in 17.9% (hs-cTnT) and 21.0% (hs-cTnI) of patients being classified as low risk with point estimates of the sensitivity at 99.5% and 98.9%. 41 For TIMI ≤ 1 with the LoD thresholds, 28.1% (hs-cTnT) and 35.7% (hscTnI) of patients were classified as low risk with estimates of sensitivity at 98.9% (97.3%-99.7%) and 98.4% (96.8%-99.4%). These later estimates are comparable to those of the present study for the optimal thresholds.
The History, ECG, Age, Risk, Troponin (HEART) score incorporates troponins based on arbitrary thresholds of the URL and twice the URL. Three studies have investigated HEART with a single hs-cTn measurement. In a study with hs-cTnT of 255 patients (75 with an ACS) a HEART score of ≤3 had only 93% (85%-98%) sensitivity for ACS with 33% classified as low risk. 42 Carlton et al. 43 for the endpoint of myocardial infarction within 30 days also had low sensitivity for hs-cTnT with HEART score ≤ 3 (93.7%), but for HEART ≤ 2 the sensitivity was comparable to this study (98.7% [92.4%-99.9%]) with 13.0% classified as low risk. Similarly, for hs-cTnI the sensitivity was 98.5% (91.9%-99.9%) with 13.1% low risk. As the prevalence, 8%, was lower than the current study, this suggests that for a comparable sensitivity the proportion classified as low risk for both hs-cTn assays, along with EDACS, at the derived thresholds, is better than for the HEART score. However, the results were comparable to an Italian-based study with HEART and hscTnT where there were no 30-day MACE events in the ≤3 group comprising 37.2% of the cohort. 44 The Troponin-only Manchester Acute Coronary Syndromes (T-MACS) aid incorporates hs-cTnT through a logistic regression model which included other risk factors and produces a probability of ACS. 45 In the validation study the probability threshold used for low risk had a sensitivity of 98.8% (95.9%-99.9%) for myocardial infarction with an impressive 66.6% classified as low or very low risk. An external validation cohort had fewer low-or verylow-risk patients (34.2%) with a sensitivity of 95.7% for 30-day MACE. 46 The ESC guidelines recommend that any single biomarker LoD threshold for classifying patients as low risk be only used in patients with blood sampling 3 hours following symptom onset. We did not limit our study to this population as we sought to derive an optimal combination for all patients irrespective of time from symptom onset. It is a strength of the process that we were able to do so.
LIMITATIONS
One possible limitation is that adjudication of AMI was done using a troponin I reference assay which some may contend would bias the results because of the purported higher specificity for hs-cTnI. However, research has shown that adjudication using hs-cTnI does not necessarily lead to an increase in MI diagnosis and may result in fewer false positives than with cTnI. 47, 48 While a procedure was used to smooth the contours used to obtain the optimal thresholds, this is a limitation. To have robust estimates of the optimal combination of thresholds without such a procedure there would need to be many times more adverse outcomes. Such massive data repositories of hs-cTn and EDACS are to the best of our knowledge not yet available anywhere in the world. Nevertheless, independent validation is necessary, not least because as with most derivation studies, the results are likely to overestimate diagnostic performance.
Furthermore, the choice to use as a target threshold a minimum sensitivity of 98.5% is necessarily arbitrary because there is no agreed-upon international standard, and different physicians may accept different levels of risk of false negatives. We chose 98.5% because we first excluded patients with evidence of new ischemia on the ECG, who would not be consider low risk, thereby decreasing the denominator without changing the possible number of false negatives. Because 11% of the cohort had such a positive ECG the percentages low risk in this study will be higher than if they had been able to be included (multiply the percentages low risk in the results section by [1-0.11]). This is important for comparison to other studies.
Ninety-one of the included patients were assessed using the EDACS tool during the EDACS-RCT. 3 Thirty-one of these patients were discharged home from ED within 6 hours and none had a 30-day MACE. As these numbers are a very small fraction of the total cohort, it is very unlikely that use of the EDACS tool introduced bias. Furthermore, any patients from any of the studies who were discharged without a diagnosis of myocardial infarction were referred for exercise stress testing within 72 hours. All readmissions over 30 days were recorded and adjudicated by at least two physicians. Nevertheless, it is possible that a myocardial infarction occurred, but was not picked up because a patient was discharged before troponin changes were observed and the stress testing was negative.
CONCLUSION
A single measurement of a high-sensitivity troponin at a threshold above the limit of detection in combination with a negative electrocardiogram and an Emergency Department Assessment of Chest Pain Score can rapidly and safely classify as low risk over 30% of patients presenting to the ED with possible acute coronary syndrome. Multiple threshold combinations can be used to improve sensitivity even more while still classifying a clinically meaningful 20% or more of patients as low risk.
